Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution

Contact Us
If you have any questions or feedback please contact us.

Connection

Allison Wheeler to Hemophilia A

This is a "connection" page, showing publications Allison Wheeler has written about Hemophilia A.

 
Connection Strength
 
 
 
4.278
 
  1. Wheeler AP, Cibelli E, Hanson G, Percier C, Porstmann T, Shridhar N, Shapiro A. Treatment and Disease Burden in a Cohort of People With Haemophilia Without Inhibitors in the United States. Haemophilia. 2025 Sep; 31(5):912-921.
    View in: PubMed
    Score: 0.771
  2. Wheeler AP, Abraham A, Barnes C, Brown Frandsen R, d'Oiron R, Eichler H, Hampton K, López-Jaime FJ, Lyu CJ, Tavares CMM, Nogami K, Sutton C, Windyga J, Zulfikar B, Castaman G. Real-World Unmet Needs of Patients With Haemophilia A and Haemophilia B With or Without Inhibitors: End-of-Study Results From the explorer6 Non-Interventional Study. Haemophilia. 2025 Sep; 31(5):903-911.
    View in: PubMed
    Score: 0.763
  3. Wheeler AP, Lim MY, Huguelet PS, Jaffray J, Staber JM, Funkhouser K, Carpenter SL, Weyand AC. Trends in dedicated care for females with bleeding disorders within U.S. hemophilia treatment centers. Am J Hematol. 2023 12; 98(12):E399-E402.
    View in: PubMed
    Score: 0.684
  4. Croteau SE, Wang M, Wheeler AP. 2021 clinical trials update: Innovations in hemophilia therapy. Am J Hematol. 2021 01; 96(1):128-144.
    View in: PubMed
    Score: 0.559
  5. Buckner TW, Kessler C, Castaman G, Hermans C, Jiménez-Yuste V, Mahlangu J, Miesbach W, Oldenburg J, Recht M, Valentino LA, Wheeler AP, Pipe SW. Pain Reduction Following Eptacog Beta Treatment of Bleeding Episodes in Adolescents and Adults With Haemophilia A or B Complicated by Inhibitors. Haemophilia. 2025 Jul; 31(4):713-721.
    View in: PubMed
    Score: 0.192
  6. Jiang D, Wang M, Wheeler AP, Croteau SE. 2025 Clinical Trials Update on Hemophilia, VWD, and Rare Inherited Bleeding Disorders. Am J Hematol. 2025 04; 100(4):666-684.
    View in: PubMed
    Score: 0.188
  7. Chowdary P, Angchaisuksiri P, Apte S, Astermark J, Benson G, Chan AKC, Jiménez Yuste V, Matsushita T, Høgh Nielsen AR, Sathar J, Sutton C, ?aulyte Trakymiene S, Tran H, Villarreal Martinez L, Wheeler AP, Windyga J, Young G, Thaung Zaw JJ, Eichler H. Concizumab prophylaxis in people with haemophilia A or haemophilia B without inhibitors (explorer8): a prospective, multicentre, open-label, randomised, phase 3a trial. Lancet Haematol. 2024 Dec; 11(12):e891-e904.
    View in: PubMed
    Score: 0.184
  8. Batsuli G, Wheeler AP, Weyand AC, Sidonio RF, Young G. Severe muscle bleeds in children and young adults with hemophilia A on emicizumab prophylaxis: Real-world retrospective multi-institutional cohort. Am J Hematol. 2023 10; 98(10):E285-E287.
    View in: PubMed
    Score: 0.169
  9. Shapiro AD, Angchaisuksiri P, Astermark J, Benson G, Castaman G, Eichler H, Jiménez-Yuste V, Kavakli K, Matsushita T, Poulsen LH, Wheeler AP, Young G, Zupancic-?alek S, Oldenburg J, Chowdary P. Long-term efficacy and safety of subcutaneous concizumab prophylaxis in hemophilia A and hemophilia A/B with inhibitors. Blood Adv. 2022 06 14; 6(11):3422-3432.
    View in: PubMed
    Score: 0.156
  10. Shapiro AD, Angchaisuksiri P, Astermark J, Benson G, Castaman G, Chowdary P, Eichler H, Jiménez-Yuste V, Kavakli K, Matsushita T, Poulsen LH, Wheeler AP, Young G, Zupancic-Salek S, Oldenburg J. Subcutaneous concizumab prophylaxis in hemophilia A and hemophilia A/B with inhibitors: phase 2 trial results. Blood. 2019 11 28; 134(22):1973-1982.
    View in: PubMed
    Score: 0.131
  11. Croteau SE, Cheng D, Cohen AJ, Holmes CE, Malec LM, Silvey M, Thornburg CD, Wheeler AP, Kouides PA, Raffini LJ, Neufeld EJ. Regional variation and cost implications of prescribed extended half-life factor concentrates among U.S. Haemophilia Treatment Centres for patients with moderate and severe haemophilia. Haemophilia. 2019 Jul; 25(4):668-675.
    View in: PubMed
    Score: 0.125
  12. Curry N, Albayrak C, Escobar M, Andre Holme P, Kearney S, Klamroth R, Misgav M, Négrier C, Wheeler A, Santagostino E, Shima M, Landorph A, Tønder SM, Lentz SR. Once-weekly prophylaxis with glycoPEGylated recombinant factor VIII (N8-GP) in severe haemophilia A: Safety and efficacy results from pathfinder 2 (randomized phase III trial). Haemophilia. 2019 May; 25(3):373-381.
    View in: PubMed
    Score: 0.124
  13. Sood SL, Cheng D, Ragni M, Kessler CM, Quon D, Shapiro AD, Key NS, Manco-Johnson MJ, Cuker A, Kempton C, Wang TF, Eyster ME, Kuriakose P, von Drygalski A, Gill JC, Wheeler A, Kouides P, Escobar MA, Leissinger C, Galdzicka S, Corson M, Watson C, Konkle BA. A cross-sectional analysis of cardiovascular disease in the hemophilia population. Blood Adv. 2018 06 12; 2(11):1325-1333.
    View in: PubMed
    Score: 0.118
  14. McGuinn C, Cheng D, Aschman D, Carpenter SL, Sidonio R, Soni A, Tarantino MD, Wheeler AP, Dunn AL. Radionuclide synovectomy/synoviorthesis (RS) in patients with bleeding disorders: A review of patient and procedure demographics and functional outcomes in the ATHNdataset. Haemophilia. 2017 Nov; 23(6):926-933.
    View in: PubMed
    Score: 0.112
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.

Copyright © 2026 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)